Transfer factor therapy in the Wiskott-Aldrich syndrome. Results of long-term follow-up in 32 patients.
Thirty-two patients with the Wiskott-Aldrich syndrome have been treated with transfer factor provided by this laboratory. Apparent clinical benefit was observed in 44 per cent of them. The mean age of the patients who showed clinical benefit was significantly greater than that of the patients who showed no benefit. Conversion of immunologic reactivity correlated with clinical benefit. Thirteen of the patients who received transfer factor are alive, and 17 have died (43 per cent survival). Clinical benefit was correlated with survival. The median survival was greater than five years in the patients who showed clinical benefit, whereas it was 18 months in those who did not show clinical benefit. We conclude that transfer factor caused conversion of immunologic parameters, apparent clinical benefit and prolonged survival in some, but not all, patients with the Wiskott-Aldrich syndrome.
D000293:Adolescent; D000367:Age Factors; D000937:Antigen-Antibody Reactions; D001772:Blood Cell Count; D001792:Blood Platelets; D002648:Child; D002675:Child, Preschool; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D014165:Transfer Factor / Q000627:therapeutic use*; D014923:Wiskott-Aldrich Syndrome / Q000276:immunology / Q000401:mortality / Q000628:therapy*
D014165:Transfer Factor